Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases

Journal of Neuropathology and Experimental Neurology

Volumn 62, Issue 1, 2003, Pages 25-33

  Aboul Enein, Fahmy ^e   Rauschka, Helmut ^a   Kornek, Barbara ^e   Stadelmann, Christine ^b   Stefferl, Andreas ^e   Brück, Wolfgang ^b   Lucchinetti, Claudia ^e   Schmidbauer, Manfred ^a   Jellinger, Kurt ^c   Lassmann, Hans ^d  

^a GENERAL HOSPITAL LINZ   (Austria)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e NONE

Author keywords

Brain hypoxia; HIF I; Multiple sclerosis; Myelin associated glycoprotein; Virus encephalitis

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; MYELIN; MYELIN ASSOCIATED GLYCOPROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; BRAIN DISEASE; CELL HYPOXIA; CELL TYPE; CONTROLLED STUDY; DEMYELINATING DISEASE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; METABOLIC ENCEPHALOPATHY; MULTIPLE SCLEROSIS; NERVE FIBER; OLIGODENDROGLIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STROKE; TISSUE INJURY; VIRUS ENCEPHALITIS; WHITE MATTER;

EID: 0037226838     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/62.1.25     Document Type: Article

References (49)

1. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000;47: 707-17
2. Trapp BD, Quarles RH. Immunocytochemical localization of the myelin-associated glycoprotein. J Neuroimmunol 1984;6:231-49
3. Trapp BD. Myelin associated glycoprotein: Location and potential functions. Ann NY Acad Sci 1990;605:29-43
4. Gendelman HE, Pezeshkpour GM, Pressman NJ, et al. A Quantitation of myelin-associated glycoprotein and myelin basic protein loss in different demyelinating diseases. Ann Neurol 1985;18:324-28
5. Itoyama Y, Sternberger NH, Webster HdeF, Quarles RH, Cohen SR, Richardson EP. Immunocytochemical observations on the distribution of myelin-associated glycoprotein and myelin basic protein in multiple sclerosis lesions. Ann Neurol 1980;7:167-77
6. Itoyama Y, Webster HdeF, Sternberger NH, et al. Distribution of papovavirus, myelin-associated glycoprotein and myelin basic protein in progressive multifocal leukoencephalopathy lesions. Ann Neurol 1982;11:396-407
7. Ludwin SK, Johnson ES. Evidence of a "dying-back" gliopathy in demyelinating disease. Ann Neurol 1981;9:301-5
8. Rodriguez M. Virus-induced demyelination in mice: "Dying-back" of oligodendrocytes. Mayo Clin Proc 1995;60:433-38
9. Vass K, Lassmann H, Wekerle H, Wisniewski HM. The distribution of Ia-antigen in the lesion of rat acute experimental allergic encephalomyelitis. Acta Neuropathol (Berl) 1986;70:149-60
10. Doberson MJ, Hammer JA, Noronha AB, et al. Generation and characterization of mouse monoclonal antibodies to myelin associated glycoprotein (MAG). Neurochem Res 1985;10:499-513
11. Piddlesden S, Lassmann H, Zimprich F, Morgan BP, Linington C. The demyelinating potential of antibodies to myelin oligodendroglia glycoprotein is related to their ability to fix complement. Am J Pathol 1993;143:555-64
12. Suzuki S, Sawa H, Komagome R, et al. Broad distribution of the JC virus receptor contrasts with a marked cellular restriction of virus replication. Virology 2001;286:100-12
13. Gold R, Schmied M, Giegrich G, et al. Differentiation between cellular apoptosis and necrosis by combined use of in situ tailing and nick translation techniques. Lab Invest 1994;71:219-25
14. Brück W, Porada P, Poser S, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995;38: 788-96
15. Kerr J, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57
16. Semenza GL. Surviving ischemia: Adaptive responses mediated by hypoxia-inducible factor 1. J Clin Invest 2000;106:809-12
17. Brunner C, Lassmann H, Waehneldt TV, Matthieu JM, Linington C. Differential ultrastructural location of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2′,3′-cyclic nucleotide 3′-phosphodiesterase in the CNS of adult rats. J Neurochem 1989;52: 296-304
18. Waxman SG, Black JA, Stys PK, Ransom BR. Ultrastructural concomitants of anoxic injury and early post-anoxic recovery in rat optic nerve. Brain Research 1992;574:105-19
19. Inuzuka T, Sato S, McIntyre LJ, Quarles RH. Effects of trypsin and plasmin pretreatment of myelin on the myelin-associated glycoprotein and basic protein. J Neurochem 1984;43:582-85
20. Moller JR, Yanagisawa K, Brady RO, Tourtellotte WW, Quarles RH. Myelin associated glycoprotein in multiple sclerosis lesions: A quantitative and qualitative analysis. Ann Neurol 1987;22:469-74
21. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120:393-99
22. Kornek B, Storch M, Weissert R, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive and remyelinated lesions. Am J Pathol 2000;157:267-76
23. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transsection in the lesions of multiple sclerosis. New Engl J Med 1998;338:278-85
24. Wender M, Wajgt A, Michalowska G, Tokarz E. Myelin associated glycoprotein (MAG) in Wallerian degeneration of the optic nerve. Exp Pathol 1984;25:125-27
25. Martinez AMB. Distribution of sodium and potassium channels as well as myelin associated glycoprotein (MAG) during early stages of Wallerian degeneration. J Submicrosc Cytol Pathol 1999;31:73-81
26. Leist M, Jaatela M. Four deaths and a funeral: From caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001;2:589-98.
27. Prineas JW, McDonald IW. Demyelinating diseases. In: DI Graham, PL Lantos, eds. Greenfield's neuropathology, Sixth Edition. London: Arnold, 1997:813-96
28. Esiri MM, Kennedy PGE. Viral diseases. In: Graham DI, Lantos PL, eds. Greenfield's neuropathology II. London: Arnold, 1997:3-63
29. Gray F. Lesions of the central nervous system in the early stages of human immunodeficiency virus infection. Rev Neurol Paris 1997;153:629-40
30. Wong KT. Emerging and reemerging epidemic encephalitis: A tale of two viruses. Neuropathol Appl Neurobiol 2000;26:313-18
31. Adams CW. Perivascular iron deposition and other vascular damage in multiple sclerosis. J Neurol Neurosurg Psychiatry 1988; 51:260-65
32. Putnam TJ. The pathogenesis of multiple sclerosis: a possible vascular factor. N Engl J Med 1933;209:786-90
33. Wakefield AJ, More LJ, Difford J, McLaughlin JE. Immunohisto-chemical study of vascular injury in acute multiple sclerosis. J Clin Pathol 1994;47:129-33
34. Lee JM, Zipfel GJ, Choi DW. The changing landscape of ischaemic brain injury mechanisms. Nature (Supp) 1999;399:A7-A14
35. Minagar A, Jy W, Jimenez JJ, et al. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology 2001;56:1319-24
36. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 1986;19:105-11
37. Lipton SA. Neuronal injury associated with HIV-1: Approaches and treatment. Annu Rev Pharmacol Toxicol 1998;38:159-77
38. McDonald JW, Althomsons SP, Hyrc KL, Choi DW, Goldberg ME Oligodendrocytes from forebrain are highly vulnerable to AMPA/ kainate receptor-mediated excitotoxicity. Nat Med 1998;4:291-97
39. Oka A, Belliveau MJ, Rosenberg PA, Volpe JJ. Vulnerability of oligodendroglia to glutamate: Pharmacology, mechanisms, and prevention. J Neurosci 1993;13:1441-53
40. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000;6:67-70
41. Smith T, Groom A, Zhu B, Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 2000;6:62-66
42. Werner P, Pitt P, Raine CS. Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001;50:169-80
43. Bitsch A, Wegener C, Da Costa C, et al. Lesion development in Marburg's type of acute multiple sclerosis: From inflammation to demyelination. Multiple Sclerosis 1999;5:138-46
44. De Groot CJ, Ruuls SR, Theeuwes JW, Dijkstra CD, van der Valk P. Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J Neuropathol Exp Neurol 1997;56:10-20
45. Liu JS, Zhao ML, Brosnan CF, Lee SC. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol 2001;158:2057-66
46. Cross AH, Manning PT, Keeling RM, Schmidt RE, Misko TP. Peroxynitrite formation within the central nervous system in active multiple sclerosis. J Neuroimmunol 1998;88:45-56
47. Beltran B, Mathur A, Duchen MR, Erusalimsky JD, Moncada S. The effect of nitric oxide on cell respiration: A key to understanding its role in cell survival or death. Proc Natl Acad Sci U S A 2000;97:14602-7
48. Brorson JR, Schumacker PT, Zhang H. Nitric oxide acutely inhibits neuronal energy production. J Neurosci 1999;19:147-58
49. Kimura H, Weisz A, Kurashima Y, et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: Control of hypoxia-inducible factor 1 activity by nitric oxide. Blood 2000;97:9082-87